 |
2 Diseases |  |
32 Trials |
|
32 Trials |  |
1662 News |  |
| «12...13141516171819202122232425 |
- | Prevymis (letermovir) / Merck (MSD)
Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. (Pubmed Central) - Jan 9, 2018
P3
Adverse events with letermovir were mainly of low grade. (Funded by Merck; ClinicalTrials.gov number, NCT02137772 ; EudraCT number, 2013-003831-31 .).
- ||||||| Prevymis (letermovir) / Merck (MSD)
Trial completion: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (clinicaltrials.gov) - Dec 9, 2016
P3, N=570, Completed, Sponsor: Merck Sharp & Dohme Corp.
(Funded by Merck; ClinicalTrials.gov number, NCT02137772 ; EudraCT number, 2013-003831-31 .). Active, not recruiting --> Completed
- ||||| Prevymis (letermovir) / Merck (MSD)
Enrollment closed: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (clinicaltrials.gov) - Mar 14, 2016
P3, N=540, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Prevymis (letermovir) / Merck (MSD)
Trial primary completion date: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (clinicaltrials.gov) - Nov 8, 2015
P3, N=540, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Aug 2016
- |||||| Prevymis (letermovir) / Merck (MSD)
Enrollment open: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (clinicaltrials.gov) - Jun 27, 2014
P3, N=540, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jan 2017 --> Aug 2016 Not yet recruiting --> Recruiting
- |||||||||| Prevymis (letermovir) / Merck (MSD)
New P3 trial: Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) (clinicaltrials.gov) - May 12, 2014
P3, N=540, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||| Prevymis (letermovir) / Merck (MSD)
Trial completion: Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients (clinicaltrials.gov) - Jul 10, 2012
P2, N=133, Completed, Sponsor: AiCuris GmbH & Co.KG
Not yet recruiting --> Recruiting Active, not recruiting --> Completed